Reading CRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRMD free→Reading CRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRMD free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but earnings quality and management's track record are neutral. Risk is elevated, and the sector backdrop is a headwind, although CRMD trades above typical compared to sector peers. Peer multiples imply a price about 77% above where it trades (it looks cheap on this basis); the read is cheap, quality intact. This assessment hinges on sector trends, particularly the performance of major healthcare companies and any potential guidance changes from CRMD. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 4 valuation methods, at three horizons. Current price $8.66. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $8.66 CRMD trades at 4× p/e, below its 16× p/e peer median. Our $38 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 77% below a flat-multiple fair value, below our forecast of about -60%. This describes what's priced in, not a forecast of the move.
Only weak execution quality — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.09x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates.
8 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.28 → $0.23 (-15.6% / 30d). 3 raised, 2 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
0 positive, 1 negative / 30d. See F4 management tile for the event list.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$146.
How much price usually moves either way.
On a bad day, this stock has moved -$517.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,226.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The lawsuit outcome may change CorMedix's market position and revenue.
Confirms:The court rules in favor of CorMedix, affirming its patents.
Disproves:The court rules against CorMedix, weakening its patent claims.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for CRMD yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Regulation FD Disclosure On June 8, 2026, CorMedix, Inc. (the “Company”) issued a press release on the decision by the United States Court of Appeals for the Federal Circuit in Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc. , which affirmed the district court’s judgment that Nexus Pharmaceuticals Inc.’s generic minocycline product infringed two of the Company’s patents and rejected Nexus’s invalidity challenge. A copy of the press release is furnished as Exhibit 99.1, attach…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
CRMD CorMedix, Inc. | Above typical Show detailsSector percentile: 75 of 100 | inexpensive | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 86 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
CorMedix has increased its full-year 2026 net revenue guidance to a range of $325 to $345 million.
CorMedix has set its full-year adjusted EBITDA guidance for 2026 to a range of $115 to $135 million.
CorMedix estimates full-year 2027 DefenCath sales in the range of $100 million to $140 million.
Results of Operations and Financial Condition On May 14, 2026, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor sh…
Regulation FD Disclosure On April 27, 2026, CorMedix, Inc. (the “Company” or “CorMedix”) issued a press release announcing an update related to the initial readout of topline data for the Phase III study (ReSPECT) assessing REZZAYO® (rezafungin for injection) for prophylaxis of invasive fungal infections. A copy of the press release is furnished as Exhibit 99.1, attached hereto. The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 o…
Results of Operations and Financial Condition On March 5, 2026, CorMedix Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilitie…
Regulation FD Disclosure On March 6, 2026, CorMedix, Inc. (the “Company” or “CorMedix”) released an updated investor presentation, which is furnished as Exhibit 99.1, attached hereto. CorMedix is also reaffirming the guidance it previously provided in its press release, dated January 8, 2026, that the Company currently estimates full-year 2027 DefenCath sales in the range of $100 million to $140 million, notwithstanding an inadvertent statement regarding this guidance on its March 5, 2026 ear…